ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Expression of DNA methyltransferase 1 is a hallmark of melanoma, correlates with response to BRAF and MEK inhibition and with proliferation in melanocytic tumors.

Maximilian Gassenmaier; Maximilian Rentschler; Birgit Fehrenbacher; Thomas Kurt Eigentler; Kristian Ikenberg; Corinna Kosnopfel; Tobias Sinnberg; Heike Niessner; Hans Bösmüller; Nikolaus Benjamin Wagner; Martin Schaller; Claus Garbe; Martin RöckenUniversity Hospital Zurich
American Journal of Pathology2020-7-15DOI: 10.1016/j.ajpath.2020.07.002
9阅读
引用收藏
分享

摘要

ABSTRACT<br/><br/>Aberrant DNA methylation is an epigenetic hallmark of melanoma and hypomethylating drugs with immunomodulatory activity are currently investigated in clinical trials. DNA methyltransferase 1 (DNMT1) is the major maintenance methyltransferase but its expression in melanocytic tumors is unknown. We analyzed DNMT1 expression in primary melanocytes, melanoma cell lines and 83 melanocytic tumors and explored its association with proliferation, mutational status and response to BRAF and MEK inhibition. We found that DNMT1 expression increased incrementally from nevi (mean fluorescence intensity (MFI) 48.1, interquartile range (IQR) 41.7 – 59.6) to primary melanomas (MFI 68.8, IQR 58.4 – 77.0) and metastatic melanomas (MFI 87.5, IQR 77.1 – 114.5; P < 0.001). DNMT1 expression correlated with Ki67 expression (Spearman correlation 0.483; P < 0.001) and was independent of the BRAF mutational status (P = 0.55). In BRAF mutant melanoma, DNMT1 was downregulated during response to BRAF and MEK inhibition and was again upregulated upon drug resistance in vitro and in vivo. Degradation of DNMT1 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid decreased cell viability in BRAF inhibitor sensitive and resistant cell lines. Our study demonstrates that DNMT1 expression correlates with proliferation in melanocytic tumors, increases with melanoma progression and is associated with response to BRAF and MEK inhibition. Given its strong expression in metastatic melanoma, DNMT1 may be a promising target for combined epigenetic and immunotherapy.

相关
加载中…
  • Oncogenic DNA methyltransferase 1 activates the PI3K/AKT/mTOR signalling by blocking the binding of HSPB8 and BAG3 in melanoma
    Yang, Yemei; Ma, Shengfang; Ye, Zi; Zheng, Yushi; Zheng, Zhenjiong; Liu, Xiongshan; Zhou, Xianyi*Epigenetics, 2023, 18(1): 2239607.
  • 黑色素瘤全基因组DNA甲基化与组蛋白甲基化异常谱式的研究
    龙海*博士, 中南大学, 2011-05-01.
  • Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma
    Pradhan, Dinesh; Milton, Denai; Vasudevaraja, Varshini; Tetzlaff, Michael; Nagarajan, Priyadharsini; Curry, Jonathan; Ivan, Doina; Long, Lihong; Ding, Yingwen; Ezhilarasan, Ravesanker; Sulman, Erik; Hwu, Wen-Jen; Prieto, Victor; Torres-Cabala, Carlos; Aung, Phyu109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Los Angeles, CA, 2020-02-29 To 2020-03-05.
查看全部 →

发表信息

论文状态
公开发表
期刊
American Journal of Pathology
发表日期
2020-07-15
DOI
10.1016/j.ajpath.2020.07.002
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
2区
成果收录
SCIENCEDIRECT

作者

  • M

    Maximilian Gassenmaier (第一作者)

  • M

    Maximilian Rentschler

查看全部 13 位作者收起作者
  • B

    Birgit Fehrenbacher

  • T

    Thomas Kurt Eigentler

  • K

    Kristian Ikenberg

  • C

    Corinna Kosnopfel

  • T

    Tobias Sinnberg

  • H

    Heike Niessner

  • H

    Hans Bösmüller

  • N

    Nikolaus Benjamin Wagner

  • M

    Martin Schaller

  • C

    Claus Garbe

  • M

    Martin Röcken

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417